The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...

Dr Sara Brenner, the FDA's principal deputy commissioner, has paused the approval process for Novavax's Covid-19 vaccine by ...

The agency is sitting on a decision to grant full approval for Novavax’s shot, days after top vaccine regulator pushed out.

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...

US biotech Novavax (Nasdaq: NVAX) is still waiting on a decision from the Food and Drug Administration over full approval of its protein-based COVID-19 vaccine, despite the agency having set an April ...

The FDA was scheduled to release its decision on Novavax’s updated, protein-based COVID-19 vaccine on April 1.

Novavax's COVID-19 vaccine received FDA Emergency Use Authorization, but full approval faces delays as regulators request more data beyond the April 1 deadline.

WASHINGTON, April 3, 2025 (BSS/AFP) - The US drug regulator has missed a deadline for granting full approval to Novavax's ...

Shares of Novavax Inc. NVAX slid 6.35% to $5.60 Thursday, on what proved to be an all-around dismal trading session for the ...

Yahoo Finance Senior Reporter Anjalee Khemlani joins Morning Brief to discuss how this leadership change could impact companies like Moderna, Novavax (NVAX), and others in the healthcare industry. To ...